Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV5-hRKp.RPGR in X-linked Retinitis Pigmentosa
NCT04671433Phase 3Completed
- Sponsor
- MeiraGTx
- Start
- Dec 2020
- Primary completion
- Sep 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 11
01
Overview
A Phase 3 trial of botaretigene sparoparvovec in X-linked retinitis pigmentosa (XLRP), sponsored by MeiraGTx. Started Dec 2020; status: completed.
02
Drugs
botaretigene sparoparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on NCT04671433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671433.